Format

Send to

Choose Destination
J Rheumatol. 1993 Apr;20(4):645-9.

Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy.

Author information

1
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Scotland.

Abstract

OBJECTIVE:

To determine if there is any advantage in adding hydroxychloroquine to intramuscular gold therapy in patients with rheumatoid arthritis (RA) with a suboptimal response to gold after 6 months of treatment.

METHODS:

Prospective double blind placebo controlled study at the Centre for Rheumatic Diseases, Glasgow Royal Infirmary and Gartnavel General Hospital, Glasgow. Patients--440 patients with RA began intramuscular gold therapy. One hundred forty-two patients with a suboptimal response at 6 months were randomized to receive additional treatment with hydroxychloroquine (400 mg/day) or placebo, and followed for a further 6 months. Outcome measures were erythrocyte sedimentation rate, C-reactive protein, Ritchie articular index, grip strength, visual analog pain score, duration of morning stiffness, health assessment questionnaire, and rate of side effects.

RESULTS:

There was no difference in outcome in terms of efficacy or toxicity.

CONCLUSION:

There is no justification for using a combination of intramuscular gold and hydroxychloroquine in patients with RA with a partial response to gold.

PMID:
8496858
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center